diphenylamine has been researched along with indazoles in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bamborough, P; Brown, MJ; Christopher, JA; Chung, CW; Mellor, GW | 1 |
| Bekemeier, H; Hirschelmann, R; Reimann, S; Schobess, B | 1 |
| Beale, GS; Haagensen, EJ; Kyle, S; Maxwell, RJ; Newell, DR | 1 |
| Haagensen, EJ; Harnor, SJ; Maxwell, RJ; Newell, DR; Payne, SL; Rennison, T; Smith, KM; Thomas, HD; Wilson, I | 1 |
| Akagi, K; Aster, JC; Chen, SC; Dail, M; Downing, JR; Lawrence, J; Lee, LB; Li, Q; Nakitandwe, J; O'Connor, D; Pear, WS; Sampath, D; Shannon, K; Wong, J; Xu, J | 1 |
| Goodwin, AF; Jheon, AH; Klein, OD; Tian, H; Zheng, X | 1 |
| Alexe, G; Armstrong, SA; Blachly, JS; Byrd, JC; Chu, SH; Cremer, A; Ellegast, JM; Frank, ES; Goodale, A; Häupl, B; Mohr, S; Oellerich, T; Piccioni, F; Pikman, Y; Rao, AV; Robichaud, A; Ross, L; Stegmaier, K; Walker, AR | 1 |
| Buzdin, AA; Ivanenko, KA; Khabusheva, ER; Kudryavtseva, AV; Lebedev, TD; Mareeva, SR; Morozov, AV; Prassolov, VS; Rubtsov, PM; Snezhkina, AV; Sorokin, MI; Spirin, PV | 1 |
8 other study(ies) available for diphenylamine and indazoles
| Article | Year |
|---|---|
Selectivity of kinase inhibitor fragments.
Topics: Adenine; Adenosine Triphosphate; Aniline Compounds; Binding Sites; Enzyme Inhibitors; High-Throughput Screening Assays; Indazoles; Indoles; Isoenzymes; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphotransferases; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridines; Pyrimidines; Quantitative Structure-Activity Relationship; Small Molecule Libraries | 2011 |
6-Sulfanilamidoindazole arthritis: influence of alloxan diabetes, phenylbutazone and D-penicillamine on inflammatory size, sulfhydryl groups, diphenylamine reaction and enzymes of the serum.
Topics: Alkaline Phosphatase; Animals; Arthritis; Blood Glucose; Diabetes Mellitus, Experimental; Diphenylamine; Disease Models, Animal; Indazoles; Male; Muramidase; Penicillamine; Phenylbutazone; Pyrazoles; Rats; Sulfanilamides; Sulfhydryl Compounds | 1975 |
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Topics: Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Imidazoles; Indazoles; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinolines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Topics: Animals; Antiviral Agents; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Indazoles; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Positron-Emission Tomography; Proto-Oncogene Proteins c-akt; Radiography; Sulfonamides | 2013 |
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Topics: Animals; Benzamides; Clone Cells; Diphenylamine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Indazoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; Sulfonamides | 2014 |
Ras Signaling Regulates Stem Cells and Amelogenesis in the Mouse Incisor.
Topics: Amelogenesis; Animals; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Diphenylamine; Fluorescent Antibody Technique; Incisor; Indazoles; Mice; Mitogen-Activated Protein Kinases; Models, Animal; Phosphatidylinositol 3-Kinases; Phosphorylation; ras Proteins; Signal Transduction; Stem Cells; Sulfonamides | 2017 |
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Indazoles; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Mutagenesis, Site-Directed; Mutation; Open Reading Frames; Primary Cell Culture; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Syk Kinase; Xenograft Model Antitumor Assays | 2020 |
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Diphenylamine; Humans; Indazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neuroblastoma; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridones; Pyrimidines; Pyrroles | 2022 |